AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ALTERITY THERAPEUTICS LTD

0.008

+0.00114.29%

Volume:5.35M

Turnover:42.81K

Market Cap:73.02M

PE:-2.02

High:0.008

Open:0.008

Low:0.008

Close:0.007

Loading ...

Overview Company News Filings

Alterity Therapeutics - Placement Was Conducted at a$0.011 per Share

THOMSON REUTERS

BRIEF-Alterity Therapeutics Seeks Trading Halt

Alterity Therapeutics Ltd - Seeks Trading Halt Pending Announcement on Capital Raising

THOMSON REUTERS

BRIEF-Alterity Therapeutics Raises A$2.13 Million Via At-The-Market Facility

Alterity Therapeutics Raises About AU$2.1 Million Via US Facility; Shares Soar 17%

MT Newswires Live

Alterity Therapeutics - Raises a$2.13M via Its at-the-Market Facility

THOMSON REUTERS

Alterity Therapeutics Is Maintained at Buy by Maxim Group

Alterity Therapeutics (ASX:ATH) shareholder returns have been stellar, earning 260% in 1 year

Simply Wall St.

ASX Runners of the Week: Bio-Gene, Alterity, Aston & Canterbury

The West Australian

Alterity Therapeutics Announces Positive Ath434 Phase 2 Trial Results in Multiple System Atrophy Led by Robust Clinical Efficacy

THOMSON REUTERS

Alterity Therapeutics Ltd - Ath434 Shows 48% Slowing of Clinical Progression at 50 Mg Dose

THOMSON REUTERS

Alterity Therapeutics Ltd -Ath434 Demonstrated a Favorable Safety Profile

THOMSON REUTERS

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Alterity Reports Positive Phase Two Trial Results for Multiple System Atrophy Drug Candidate, Shares Surge 125% to Record High

MT Newswires Live

Alterity Therapeutics shows positive ATH434 Phase 2 trial results for Multiple System Atrophy

BRIEF-Alterity Therapeutics Seeks Trading Halt

Alterity Therapeutics Ltd - Seeks Trading Halt Pending Announcement on Results of Phase Ii Clinical Trial

THOMSON REUTERS

Watch These Apple Price Levels After Stock Suffers Biggest One-Day Drop Since August

Watch These UnitedHealth Price Levels as Stock Slumps After Disappointing Results

Watch These Intuitive Surgical Price Levels as Stock Hits Another Record High

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATH.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATH.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","market":"AU","secType":"STK","nameCN":"ALTERITY THERAPEUTICS LTD","latestPrice":0.008,"timestamp":1745302320000,"preClose":0.007,"halted":0,"volume":5351033,"delay":0,"nameEN":"ALTERITY THERAPEUTICS LTD","floatShares":4795812943,"shares":9127370686,"eps":-0.003967,"marketStatus":"Closed","change":0.001,"latestTime":"04-22 16:12:00 AEST","open":0.008,"high":0.008,"low":0.008,"amount":42808,"amplitude":0,"askPrice":0.009,"askSize":7655341,"bidPrice":0.008,"bidSize":5130313,"shortable":3,"etf":0,"ttmEps":-0.003967,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.007,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.509931,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","floatShares":4795812943,"roa":"-78.37%","roe":"-155.77%","lyrEps":-0.00524,"volumeRatio":0.509931,"shares":9127370686,"dividePrice":0,"high":0.008,"amplitude":0,"preClose":0.007,"low":0.008,"week52Low":0.002,"pbRate":"9.38","psRate":"19.61","week52High":0.019,"institutionHeld":0,"latestPrice":0.008,"committee":-0.197489,"eps":-0.003967,"divideRate":0,"volume":5351033,"delay":0,"ttmEps":-0.003967,"open":0.008,"prevYearClose":0.008,"prevWeekClose":0.007,"prevMonthClose":0.009,"prevQuarterClose":0.009,"fiveDayClose":0.008,"twentyDayClose":0.009,"sixtyDayClose":0.009},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATH.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510307396","title":"Alterity Therapeutics - Placement Was Conducted at a$0.011 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2510307396","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510307396?lang=en_us&edition=fundamental","pubTime":"2025-02-10 07:23","pubTimestamp":1739143432,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250209:nFWN3OY2CT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2509252535","title":"BRIEF-Alterity Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2509252535","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509252535?lang=en_us&edition=fundamental","pubTime":"2025-02-06 05:55","pubTimestamp":1738792555,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Seeks Trading HaltFeb 6 (Reuters) - Alterity Therapeutics Ltd ATH.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON  CAPITAL RAISINGFurther company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW238:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2509252536","title":"Alterity Therapeutics Ltd - Seeks Trading Halt Pending Announcement on  Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2509252536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509252536?lang=en_us&edition=fundamental","pubTime":"2025-02-06 05:55","pubTimestamp":1738792530,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW238:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2508616891","title":"BRIEF-Alterity Therapeutics Raises A$2.13 Million Via At-The-Market Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2508616891","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508616891?lang=en_us&edition=fundamental","pubTime":"2025-02-03 09:31","pubTimestamp":1738546295,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Raises A$2.13 Million Via At-The-Market FacilityFeb 3 (Reuters) - Alterity Therapeutics Ltd ATH.AX:RAISES A$2.13M VIA ITS AT-THE-MARKET FACILITYFurther company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nFWN3OS06N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2508157992","title":"Alterity Therapeutics Raises About AU$2.1 Million Via US Facility; Shares Soar 17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508157992","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508157992?lang=en_us&edition=fundamental","pubTime":"2025-02-03 08:36","pubTimestamp":1738543005,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  raised about AU$2.1 million capital in the US via an at-the-market facility, according to a Monday Australian filing.The company received the opportunity to raise the capital based on positive topline results from the phase two trial in multiple system atrophy for its ATH434 drug candidate, the filing said.ATH434 is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, it added.The company also expects to receive about AU$5.7 million in rebates from the Australian Taxation Office under the government's Research and Development Tax Incentive scheme.The proceeds will allow it to advance its clinical and regulatory activities.The firm's shares soared almost 17% in early trading on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATH.AU","BK7067","XJO.AU","XAO.AU","LENZ","BK4139","XKO.AU"],"gpt_icon":0},{"id":"2508513031","title":"Alterity Therapeutics -  Raises a$2.13M via Its at-the-Market Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2508513031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508513031?lang=en_us&edition=fundamental","pubTime":"2025-02-03 06:55","pubTimestamp":1738536920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250202:nFWN3OS06N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2507604350","title":"Alterity Therapeutics Is Maintained at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2507604350","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507604350?lang=en_us&edition=fundamental","pubTime":"2025-01-31 07:00","pubTimestamp":1738278000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATHE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2025 18:00 ET (23:00 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","ATHE","LENZ"],"gpt_icon":0},{"id":"2507609958","title":"Alterity Therapeutics (ASX:ATH) shareholder returns have been stellar, earning 260% in 1 year","url":"https://stock-news.laohu8.com/highlight/detail?id=2507609958","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507609958?lang=en_us&edition=fundamental","pubTime":"2025-01-31 05:58","pubTimestamp":1738274326,"startTime":"0","endTime":"0","summary":"The most you can lose on any stock  is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. For example, the Alterity Therapeutics Limited  share price had more than doubled in just one year - up 260%. Shareholders are also celebrating an even better 500% rise, over the last three months. In contrast, the longer term returns are negative, since the share price is 14% lower than it was three years ago.Since the stock has added AU$48m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.We think companies that have neither significant revenues nor profits are pretty high risk. You should be aware that the company needed to issue more shares recently so that it could raise enough money to continue pursuing its business plan. While some such companies do very well over the long term, others become hyped up by promoters before eventually falling back down to earth, and going bankr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-therapeutics-asx-ath-shareholder-215846964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4139","BK7067","BK4162","LENZ","ATH.AU","ATHE","ATH"],"gpt_icon":0},{"id":"2507982573","title":"ASX Runners of the Week: Bio-Gene, Alterity, Aston & Canterbury","url":"https://stock-news.laohu8.com/highlight/detail?id=2507982573","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507982573?lang=en_us&edition=fundamental","pubTime":"2025-01-31 04:12","pubTimestamp":1738267925,"startTime":"0","endTime":"0","summary":"This week’s Bulls N’ Bears Runner of the Week is… Bio-Gene Technology. Their shares surged after scoring US defence grants, while Alterity Therapeutics, Aston Minerals and Canterbury Resources also ran hard.","market":"hk","thumbnail":"https://images.thewest.com.au/publication/C-17568718/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-17568718/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-bio-gene-alterity-aston-canterbury-c-17568718","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-bio-gene-alterity-aston-canterbury-c-17568718","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["BK7067","BK7020","ATH.AU","BGT.AU"],"gpt_icon":0},{"id":"2507647455","title":"Alterity Therapeutics Announces Positive Ath434 Phase 2 Trial Results in Multiple System Atrophy Led by Robust Clinical Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2507647455","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507647455?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:35","pubTimestamp":1738240500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nTUA7HSNVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2507647451","title":"Alterity Therapeutics Ltd - Ath434 Shows 48% Slowing of Clinical Progression at 50 Mg Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2507647451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507647451?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:35","pubTimestamp":1738240500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nTUA7HSNVG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2507458647","title":"Alterity Therapeutics Ltd -Ath434 Demonstrated a Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2507458647","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507458647?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:35","pubTimestamp":1738240500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nTUA7HSNVG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2507647737","title":"Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2507647737","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507647737?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:35","pubTimestamp":1738240500,"startTime":"0","endTime":"0","summary":"– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –。– Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale –。– Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions –。– ATH434 Demonstrated a Favorable Safety Profile –。– Webcast Held Yesterday with Access to the Recording Below –。“We are thrilled that ATH434 has demonstrated significant slowing of clinical progression and an excellent safety profile in this rare, rapidly progressive disease,” said David Stamler, M.D., Chief Executive Officer of Alterity. “Currently, there are no approved treatments that slow the progression of MSA and these results show that ATH434’s targeted iron engagement may truly have a disease modifying effect. The fact that we achieved statistical significance on the UMSARS is extremely meaningful because it assesses the functional areas affected in MSA and is the endpoint needed to support drug approval by the U.S. Food and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-therapeutics-announces-positive-ath434-123500870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0053671581.USD","AE","BK7067","LENZ","ATHE","LU0728928796.USD","MSA","LU2125909759.SGD","BID.AU","LU0757428866.USD","ATH.AU","LU1923622291.USD","BK4139","LU2211815571.USD","LU1815336091.USD","BK4138","LU2125909916.SGD","BK7016","BK4143"],"gpt_icon":0},{"id":"2507691790","title":"Alterity Reports Positive Phase Two Trial Results for Multiple System Atrophy Drug Candidate, Shares Surge 125% to Record High","url":"https://stock-news.laohu8.com/highlight/detail?id=2507691790","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507691790?lang=en_us&edition=fundamental","pubTime":"2025-01-30 11:10","pubTimestamp":1738206603,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ASX:ATH) reported positive topline results from the randomized, double-blind, placebo-controlled phase two clinical trial following 12 months of treatment using the ATH434 drug ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2507469991","title":"Alterity Therapeutics shows positive ATH434 Phase 2 trial results for Multiple System Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2507469991","media":"Small Caps","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507469991?lang=en_us&edition=fundamental","pubTime":"2025-01-30 07:40","pubTimestamp":1738194049,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  has announced positive topline results from a Phase 2 clinical trial of lead candidate ATH434-201 on patients with early-stage multiple system atrophy .ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.MSA is a rare neurodegenerative disease characterised by failure of the autonomic nervous system and impaired movement, with symptoms reflecting the progressive loss of function and death of different types of nerve cells in the brain and spinal cord.The randomised, double-blind, placebo-controlled trial produced a clinically meaningful benefit at both 50-milligram and 75mg doses.It also generated a 48% improvement on the modified UMSARS Part I, a functional rating scale that assesses disability in daily living activities in MSA patients.“The fact that we achieved statistical significance on the UMSARS scale is extremely meaningful because it assesses the functional areas affected by MSA and is the ","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/01/Alterity-Therapeutics-ASX-ATH-ATH434-Phase-2-Trial-Results-Multiple-System-Atrophy.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/01/Alterity-Therapeutics-ASX-ATH-ATH434-Phase-2-Trial-Results-Multiple-System-Atrophy.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/alterity-therapeutics-positive-ath434-results-multiple-system-atrophy/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["LU2125909916.SGD","LU2125909759.SGD","LU1923622291.USD","LU2211815571.USD","BK4139","MSA","LU0728928796.USD","LU0757428866.USD","LU0053671581.USD","ATH.AU","BK7067","LENZ","LU1815336091.USD","BK4143"],"gpt_icon":0},{"id":"2506538517","title":"BRIEF-Alterity Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2506538517","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506538517?lang=en_us&edition=fundamental","pubTime":"2025-01-28 05:46","pubTimestamp":1738014401,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Seeks Trading HaltJan 28 (Reuters) - Alterity Therapeutics Ltd ATH.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON  RESULTS OF PHASE II CLINICAL TRIALFurther company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nFWN3ON16L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2506388325","title":"Alterity Therapeutics Ltd - Seeks Trading Halt Pending Announcement on  Results of Phase Ii Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2506388325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506388325?lang=en_us&edition=fundamental","pubTime":"2025-01-28 05:43","pubTimestamp":1738014227,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nFWN3ON16L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2504956191","title":"Watch These Apple Price Levels After Stock Suffers Biggest One-Day Drop Since August","url":"https://stock-news.laohu8.com/highlight/detail?id=2504956191","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504956191?lang=en_us&edition=fundamental","pubTime":"2025-01-17 22:33","pubTimestamp":1737124433,"startTime":"0","endTime":"0","summary":"Apple  shares will be in focus on Friday after recording their largest one-day drop since early August yesterday following news that the tech giant lost its coveted position as China’s largest smartphone seller last year.Data from technology research firm Canalys showed the iPhone maker’s 2024 shipments slumped 17% in the country, their largest decline since 2016, as domestic rivals Vivo and Huawei both captured additional market share. The company’s latest iPhones sold in China aren’t equipped with its recently launched artificial intelligence  features due to regulatory hurdles, weighing on sales as customers turn to competitors’ devices for alternatives.Apple shares were up 1.2% at $231 in the opening minutes of trading Friday, after falling 4% yesterday. The stock is down 9% so far in 2025, after gaining 30% last year.The bulls’ inability to defend this level could see Apple shares revisit lower support at the $207 level. Investors may look for buying opportunities in this area nea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/watch-these-price-levels-as-stock-suffers-biggest-one-day-drop-since-august-8776376","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["LU0348723411.USD","LU1814569148.SGD","IE00B1XK9C88.USD","LU0048584097.USD","BK4579","LU2097344357.USD","LU0949170426.SGD","LU1934455863.HKD","LU0056508442.USD","LU0215105999.USD","LU2360032135.SGD","ATH","SG9999015341.SGD","SG9999015978.USD","IE00BK4W5M84.HKD","LU0882574139.USD","LU1366192091.USD","LU2087621335.USD","LU0985320562.USD","LU0965508806.USD","LU0314104364.USD","ATH.AU","BK4512","LU0689472784.USD","LU0444971666.USD","LU1316542783.SGD","BK4170","SGXZ31699556.SGD","IE00B775H168.HKD","LU0345769128.USD","LU0345770993.USD","IE00BFSS7M15.SGD","LU0642271901.SGD","LU0943347566.SGD","LU1571399168.USD","LU2087625088.SGD","LU0251132253.USD","AAPL","BK4533","LU0494093205.USD","IE00B1BXHZ80.USD","MACW.SI","LU0127658192.USD","LU0154236417.USD","BK4554","LU0345769631.USD","BK4550","LU0708995401.HKD","LU2023250843.SGD","LU2461242641.AUD"],"gpt_icon":1},{"id":"2504790100","title":"Watch These UnitedHealth Price Levels as Stock Slumps After Disappointing Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2504790100","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504790100?lang=en_us&edition=fundamental","pubTime":"2025-01-17 11:45","pubTimestamp":1737085511,"startTime":"0","endTime":"0","summary":"UnitedHealth Group  shares fell sharply Thursday after the health insurer reported fourth-quarter results below Wall Street’s expectations and issued a lackluster outlook amid higher medical costs.The company, which kept its 2025 outlook unchanged, said it expects a medical cost ratio —the percentage of premiums spent on medical care—of 86% to 87% this year. By comparison, the insurer’s MCR sat just a little over 82% in the first quarter of 2023.UnitedHealth shares were the biggest decliners on the S&P 500 on Thursday, falling 6% to $510.59. The stock, which is down nearly 20% from its record high set in November, is virtually unchanged from a year ago, while the S&P 500 has gained 25% in the last 12 months.Below, we break down the technicals on UnitedHealth’s chart and identify key price levels that investors may be watching after the stock’s earnings-driven decline.A breakout above this key resistance level could see the shares climb to around $605, an area where they may encounter s","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/watch-these-unitedhealth-price-levels-as-stock-slumps-after-disappointing-results-8776323","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["LU0456855351.SGD","LU1066051498.USD","ATH.AU","LU1037948541.HKD","LU1854103824.USD","LU1989771016.USD","SG9999018865.SGD","LU1674673428.USD","LU1791710400.SGD","LU0048584097.USD","IE00B1BXHZ80.USD","LU1057294990.SGD","LU2279689827.SGD","LU0943347566.SGD","LU1983299246.USD","IE00BFSS7M15.SGD","LU1670627923.USD","BK4581","LU0820561818.USD","MCR.AU","IE00B4R5TH58.HKD","LU1934455194.USD","LU1061106388.HKD","MCR","SGXZ99366536.SGD","SG9999014880.SGD","IE00B7SZLL34.SGD","LU0203345920.USD","LU0158827781.USD","LU0689472784.USD","LU0861579265.USD","IE0002270589.USD","LU1323610961.USD","LU2236285917.USD","LU2087625088.SGD","LU1720051108.HKD","LU2461242641.AUD","LU0557290698.USD","BK7067","IE00B19Z9505.USD","IE00B1XK9C88.USD","LU0256863811.USD","SG9999017495.SGD","LU0211328371.USD","IE00B19Z8W00.USD","LU1153585028.USD","UNH","BK4162","ATH","IE00B19Z8X17.USD"],"gpt_icon":1},{"id":"2504927371","title":"Watch These Intuitive Surgical Price Levels as Stock Hits Another Record High","url":"https://stock-news.laohu8.com/highlight/detail?id=2504927371","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504927371?lang=en_us&edition=fundamental","pubTime":"2025-01-17 06:45","pubTimestamp":1737067535,"startTime":"0","endTime":"0","summary":"Intuitive Surgical shares hit another record high Thursday as investor sentiment runs high amid growing demand for the company's surgical robotics equipment.The stock has traded within an extended rising wedge since early February last year, keeping the price confined within the pattern’s two converging upward sloping trendlines.The measuring principle, which calculates the distance of the rising wedge near its widest point and adds that amount to the pattern’s top trendline, projects an upside target of $650.Investors should watch major support levels on Intuitive Surgical's chart around $550 and $520.Intuitive Surgical  shares hit another record high Thursday, one day after the medical technology company issued preliminary fourth-quarter and full-year revenue above expectations amid growing demand for its surgical robotics equipment.During pullbacks, investors should initially keep a close eye on the $550 level. The shares could attract buying interest in this area near the low of We","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/watch-these-intuitive-surgical-price-levels-stock-hits-another-record-high-8775500","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["LU2023250843.SGD","LU1923623000.USD","BK4534","LU1917777945.USD","LU0390134368.USD","LU1804176565.USD","LU1057294990.SGD","LU1023059063.AUD","LU0823434740.USD","LU1951200564.SGD","BK4585","LU1868836757.USD","LU2023250504.SGD","LU0097036916.USD","LU1868836591.USD","LU2106854487.HKD","LU0289739699.SGD","LU1974910355.USD","LU0058720904.USD","IE00B19Z8W00.USD","IE00B19Z9505.USD","LU1989764664.SGD","LU2265009873.SGD","LU1868837300.USD","BK7067","BK4504","IE00B19Z8X17.USD","IE00BYQQ9H92.USD","LU0354030511.USD","IE00BFXG0V08.USD","LU0823434583.USD","LU1061106388.HKD","LU0122379950.USD","ATH","LU0079474960.USD","BK4082","IE00B5TLWC47.USD","LU1951198990.SGD","LU0114720955.EUR","LU0061475181.USD","ATH.AU","LU0882574055.USD","LU0354030438.USD","ISRG","BK4548","LU1868836914.USD","LU0823416689.USD","LU1868837136.USD","LU0096364046.USD","BK4162"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":62,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATH.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATH.AU\",market:\"AU\",,,undefined,":[]}}